EuroPCR 2018 | LEADERS FREE: Complex Angioplasty in Patients with High Risk for Bleeding

The LEADERS FREE study showed that a biolimus A9-coated polymer-free stent was superior to a conventional stent in terms of safety and efficacy in patients who received dual antiplatelet therapy for only a month due to their high risk for bleeding.

EuroPCR 2018 | LEADERS FREE: angioplastias complejas en pacientes con alto riesgo de sangradoIn this substudy, researchers analyzed 667 patients enrolled in the original LEADERS FREE trial who met certain requirements for complex angioplasty: total stent length >60 mm, 3-vessel lesions, 3 or more implanted stents, bifurcation lesions requiring 2 stents, total occlusions, restenosis, or lesions in saphenous vein grafts. All these high-risk patients were randomized to biolimus A9-coated polymer-free stent or conventional stent. The risk of bleeding for these patients who had undergone complex angioplasty was even higher than the mean risk for the whole study population.


Read also: EuroPCR 2018 | SPYRAL HTN-ON MED: Renal Denervation Comes Back to Life.


The biolimus-eluting stent showed benefit both in terms of safety (16.2% vs. 21.7%; hazard ratio [HR]: 0.70 [0.49-0.99]; p < 0.05) and efficacy (10.8% vs. 18.1%; HR: 0.54 [0.35-0.83]; p < 0.005). However, for the 1746 patients who had undergone complex angioplasty, the relative difference in efficacy was even higher than for the general population (5.3% vs. 9.9%; HR: 0.52 [0.36-0.75]; p < 0.001), while safety was similar to that shown by conventional stents (11.1% vs. 12.6%).

 

Original title: LEADERS FREE: Complex PCI for Patients at High Bleeding Risk – Two Year Outcome of a Substudy.

Presenter: Philip Urban.

LEADERS-FREE


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...